Benzinga | Jan 25, 2021 09:34AM EST

Aegis Capital Maintains Buy on VolitionRX, Raises Price Target to $10

Aegis Capital analyst Nathan Weinstein maintains VolitionRX (AMEX:VNRX) with a Buy and raises the price target from $8 to $10.